Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O00222
UPID:
GRM8_HUMAN
Alternative names:
-
Alternative UPACC:
O00222; A4D0Y3; B0FZ74; B0M0L0; O15493; O95945; O95946; Q3MIV9; Q52M02; Q6J165
Background:
Metabotropic glutamate receptor 8 (mGluR8) plays a pivotal role in neurotransmission, acting as a G-protein coupled receptor for glutamate. Upon glutamate binding, mGluR8 undergoes a conformational change, initiating signaling through G proteins. This signaling cascade results in the modulation of adenylate cyclase activity, crucial for various cellular processes.
Therapeutic significance:
Understanding the role of Metabotropic glutamate receptor 8 could open doors to potential therapeutic strategies. Its involvement in modulating adenylate cyclase activity highlights its potential as a target in neurological disorders where glutamate signaling is dysregulated.